Back to Continuing Education

Want to buy for someone else? You can purchase a token at check out.

Overview
Goals and Outcomes
Details
Accreditations
Overview
Overview
Stroke is the fifth-leading cause of death in the U.S. While 87% of strokes are the result of ischemia, only one drug is approved for acute treatment and then only within a narrow treatment window. Research is key to developing new treatments and preventive strategies. This educational activity will address the clinical trial process and the roles and implications for nurses caring for participants in trials.
Goals and Outcomes
Goals and Learning Outcomes
The goal of this continuing education program is to provide nurses with an overview of the new-drug approval process and the potential nursing roles in stroke clinical trials for investigational drugs. After studying the information presented here, you will be able to:
  • Describe the phases of clinical trials for U.S. Food and Drug Administration approval of new drugs
  • Explain the multiple roles of nurses who care for patients during stroke clinical trials
  • List typical adverse effects of drugs under investigation for strokes and complications of strokes
Details
Course Details

Course Originally Released on : 8/26/2002

CE292-60

Course Author

Janice L. Hinkle

PhD, RN, CNRN

Accreditations
Accreditations

NURSES
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Provider approved by the California Board of Registered Nursing, CEP#13791

Accreditations imageAccreditations image

Disclaimer: Not all courses will provide California Board of Registered Nursing approval. Per California Assembly Bill No. 241, continuing education courses related to direct patient care shall address at least one or a combination of the following:(1) Examples of how implicit bias affects perceptions and treatment decisions of licensees, leading to disparities in health outcomes; or (2) Strategies to address how unintended biases in decision-making may contribute to health care disparities by shaping behavior and producing differences in medical treatment along lines of race, ethnicity, gender identity, sexual orientation, age, socioeconomic status, or other characteristics.

CEBroker
Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and West Virginia Board Of Examiners For Registered Professional Nurses
Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

Disclosures
None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.